Registration Frequencies
Fig 1) Patient numbers by biologic treatment at inclusion
Last update: | n=

Fig 2) PsoBest registry: patient numbers by non-biologic treatment at inclusion
Last update: | n=
Show table for Fig. 1/2Hide table
Inclusion Treatment | Patient Number | of that with similar agents (e.g. Biosimilars) |
---|---|---|
Adalimumab | 1019 | 363 |
Brodalumab | 365 | 0 |
Certolizumab | 101 | 0 |
Efalizumab | 35 | 0 |
Etanercept | 309 | 59 |
Golimumab | 25 | 0 |
Guselkumab | 608/td> | 0 |
Infliximab | 101 | 1 |
Ixekizumab | 493 | 0 |
Risankizumab | 292 | 0 |
Secukinumab | 1301 | 0 |
Tildrakizumab | 354 | 0 |
Ustekinumab | 711 | 0 |
Apremilast | 531 | 0 |
Ciclosporin | 392 | 0 |
Fumaderm | 2606 | 0 |
Skilarence | 1807 | 0 |
Methotrexate | 3269 | 0 |
Tofacitinib | 1 | 0 |
other systemics | 328 | 0 |
Fig. 3) Rate of patients by medication class at inclusion
Last update: | n=
Fig. 4) Rate of patients by type of registry site
Last update: | n=
Fig. 5) Registered PsoBest centers
Last update: | n= | updated monthly